{"Title": "Intravenous Interferon \u03b2-1a for Severe ARDS - Reply", "Year": 2020, "Source": "JAMA", "Volume": "324", "Issue": 5, "Art.No": null, "PageStart": 515, "PageEnd": 516, "CitedBy": 0, "DOI": "10.1001/jama.2020.7992", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089162064&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Administration, Intravenous", "Humans", "Interferon beta-1a", "Interferon-beta", "Multiple Sclerosis, Relapsing-Remitting", "Respiratory Distress Syndrome, Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-85089162064", "SubjectAreas": [["Medicine (all)", "MEDI", "2700"]], "AuthorData": {"6701610029": {"Name": "Bellingan G.", "AuthorID": "6701610029", "AffiliationID": "60024544", "AffiliationName": "Critical Care, University College London Hospitals"}, "7006629760": {"Name": "Ranieri V.M.", "AuthorID": "7006629760", "AffiliationID": "60028218", "AffiliationName": "Alma Mater Studiorum-Universit\u00e1 di Bologna"}, "57214992831": {"Name": "Karvonen M.K.", "AuthorID": "57214992831", "AffiliationID": "123981178", "AffiliationName": "Faron Pharmaceuticals Ltd"}}}